Synapse
⌘+K
Synapse
PulseExploreClubsResearchersJournals
Instagram
HomeClubsExplore
December 8, 2025Blood

Safety and effectiveness of brentuximab vedotin in Chinese patients with CD30-positive lymphomas: A multicenter real-world analysis

View Full Paper
Ask AI
Bookmark
Share

Authors

WQWenbin QianYLYun Liang

Discussion

Loading...

Member takes

Overview

Multicenter analysis shows high response rates and manageable adverse events in CD30-positive lymphomas treated with brentuximab vedotin.

Key Points

  • This research aimed to evaluate the safety and effectiveness of brentuximab vedotin in various CD30-positive lymphomas among Chinese patients.
  • Conducted a multicenter retrospective study from January 2020 to December 2024.
  • Included patients with different CD30-positive lymphoma subtypes such as PTCL, CTCL, cHL, and BCL.
  • Primary endpoint measured was the objective response rate (ORR) while secondary endpoints included adverse events and treatment patterns.
  • 141 patients were analyzed, showing an overall ORR of 81.6% and a complete remission rate of 48.2%.
  • Among treatment-naïve patients, cHL showed an ORR of 90.5% while PTCL had an ORR of 85.3%.
  • Adverse events were reported in 81.6% of patients, with the most common being anemia, infections, and peripheral neuropathy.

Cite This Study

Qian et al. (2025) studied this question.

synapsesocial.com/papers/69362f744fa91c937236e2a1https://doi.org/10.1182/blood-2025-7215
View Full Paper
Ask AI
Bookmark
Share